
Armata Pharmaceuticals secures patents for key bacteriophage therapies through 2041, advancing antibiotic-resistant infection treatments.
Armata Pharmaceuticals announced the issuance of two U.S. patents protecting its bacteriophage therapy candidates AP-SA02 and AP-PA02 until at least 2041. These patents strengthen Armata's intellectual property in developing treatments for antibiotic...





